NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq:NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The $600,000 grant, funded by JDRF to Yale, is a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).